Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance

Intensive Care Medicine

Volumn 44, Issue 2, 2018, Pages 189-196

  De Waele, Jan J ^a   Akova, Murat ^b   Antonelli, Massimo ^c   Canton, Rafael ^d   Carlet, Jean ^e   De Backer, Daniel ^f   Dimopoulos, George ^g   Garnacho Montero, José ^h   Kesecioglu, Jozef ⁱ   Lipman, Jeffrey ^j,k   Mer, Mervyn ^k,l   Paiva, José Artur ^m   Poljak, Mario ⁿ   Roberts, Jason A ^j   Rodriguez Bano, Jesus ^h   Timsit, Jean François ^o,p   Zahar, Jean Ralph ^p,q   Bassetti, Matteo ^r  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HACETTEPE UNIVERSITY   (Turkey)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e World Alliance Against Antibiotic Resistance (WAAAR)   (France)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^g NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^h HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^l UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^m University of Porto   (Portugal)

ⁿ UNIVERSITY OF LJUBLJANA   (Slovenia)

^o UNIVERSITÉ PARIS DESCARTES   (France)

^p UNIVERSITÉ PARIS 13   (France)

^q University Hospitals Paris Seine Saint Denis   (France)

^r Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine   (Italy)

more..

Author keywords

Antibiotic; Infection; Resistance; Stewardship

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; CONFERENCE PAPER; CRITICAL ILLNESS; HEALTH CARE ORGANIZATION; HUMAN; INFECTION; INFECTION CONTROL; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; RESPONSIBILITY;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL STEWARDSHIP; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE; HUMANS; INTENSIVE CARE UNITS;

EID: 85039731605     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-017-5036-1     Document Type: Conference Paper

References (20)

1. Tabah A, Koulenti D, Laupland K, Misset B, Valles J, de Bruzzi Carvalho F, Paiva JA, Cakar N, Ma X, Eggimann P, Antonelli M, Bonten MJ, Csomos A, Krueger WA, Mikstacki A, Lipman J, Depuydt P, Vesin A, Garrouste-Orgeas M, Zahar JR, Blot S, Carlet J, Brun-Buisson C, Martin C, Rello J, Dimopoulos G, Timsit JF (2012) Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 38:1930–1945
2. O’Neill J (2014) Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist 1–16
3. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A (2017) Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med 43:1464–1475
4. Bassetti M, De Waele JJ, Eggimann P, Garnacho-Montero J, Kahlmeter G, Menichetti F, Nicolau DP, Paiva JA, Tumbarello M, Welte T, Wilcox M, Zahar JR, Poulakou G (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–795
5. Martín-Loeches I, Diaz E, Vallés J (2014) Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care 20:516–524
6. Miller BM, Johnson SW (2016) Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: development of a bedside clinical score for risk assessment. Am J Infect Control 44:134–137
7. Bassetti M, Carnelutti A, Peghin M (2017) Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti-infect Ther 15:55–65
8. van Belkum A, Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J, Shortridge D, Engelhardt A, Dunne WM (2013) Rapid clinical bacteriology and its future impact. Ann Lab Med 33:14–27
9. Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, Dumenil AS, Lemiale V, Mourvillier B, Clec’h C, Darmon M, Laurent V, Marcotte G, Lucet JC, Souweine B, Zahar JR, Timsit JF, Outcomerea SG (2016) Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure. J Antimicrob Chemother 71:1088–1097
10. Bassetti M, Righi E, Carnelutti A (2016) New therapeutic options for respiratory tract infections. Curr Opin Infect Dis 29:178–186
11. Roberts JA, Lefrant JY, Lipman J (2017) What’s new in pharmacokinetics of antimicrobials in AKI and RRT. Intensive Care Med 43:904–906
12. Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA, Infection Section for the European Society of Intensive Care Medicine TPAPSGOTESOCMAID, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases (2017) The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 43:1021–1032
13. Tabah A, De Waele J, Lipman J, Zahar JR, Cotta MO, Barton G, Timsit JF, Roberts JA, Working Group for Antimicrobial Use in the ICU within the Infection Section of the European Society of Intensive Care Medicine ESICM (2015) The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. J Antimicrob Chemother 70:2671–2677
14. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK (2013) Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 144:1759–1767
15. Matthaiou DK, Ntani G, Kontogiorgi M, Poulakou G, Armaganidis A, Dimopoulos G (2012) An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 38:940–949
16. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, Loef BG, Dormans T, van Melsen GC, Kluiters YC, Kemperman H, van den Elsen MJ, Schouten JA, Streefkerk JO, Krabbe HG, Kieft H, Kluge GH, van Dam VC, van Pelt J, Bormans L, Otten MB, Reidinga AC, Endeman H, Twisk JW, van de Garde EM, de Smet AM, Kesecioglu J, Girbes AR, Nijsten MW, de Lange DW (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16:819–827
17. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ (2016) Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 387:176–187
18. Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M, Hryniewicz W, Empel J, Dautzenberg MJ, Annane D, Aragao I, Chalfine A, Dumpis U, Esteves F, Giamarellou H, Muzlovic I, Nardi G, Petrikkos GL, Tomic V, Marti AT, Stammet P, Brun-Buisson C, Bonten MJ (2014) Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis 14:31–39
19. Paterson DL (2004) Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl 4):S341–S345
20. Brooks BD, Brooks AE (2014) Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev 78:14–27